EPICS: Global Perspectives in Gastrointestinal Malignancies in 2022 and Beyond

Latest therapeutic developments in GI cancer treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

September 17 and 23, 2022
Howard Hochster, MD, FACP, Aptitude Health Scientific Leader

Faculty Chair

Tanios Bekaii-Saab, MD, FACP

Mayo Clinic Cancer Center

Faculty Members

Christopher Lieu, MD
University of Colorado Cancer Center

Joleen Hubbard, MD
Mayo Clinic, Rochester

Philip A. Philip, MD, PhD
Henry Ford Cancer Institute

John H. Strickler, MD
Duke Cancer Center

Julien Taieb, MD, PhD
University of Paris

Gerald Prager, MD, PhD
University of Vienna

Chiara Cremolini, MD, PhD
University of Pisa

Alan P. Venook, MD
Helen Diller Family Comprehensive Cancer Center

Scott Kopetz, MD, PhD, FACP
MD Anderson Cancer Center

Efrat Dotan, MD
Fox Chase Cancer Center

Gerald Prager, MD, PhD
University of Vienna

Sample Report

Start discovering the insights

View Report

REPORT TOPICS INCLUDE

  • Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments
  • Colorectal Cancer – Immunotherapy
  • Hepatocellular Carcinoma
  • Gastroesophageal Junction (GEJ) and Gastric Cancer
  • Rectal Cancer
  • Pancreatic Cancer and Biliary Tract Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.